Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm Co's total inventories for the quarter that ended in Mar. 2026 was NT$1,406 Mil. TTY Biopharm Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was NT$1,398 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TTY Biopharm Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was NT$-0.41.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TTY Biopharm Co's Days Inventory for the
three
months ended in Mar. 2026 was 209.66.
Inventory Turnover measures how fast the company turns over its inventory within a year.
TTY Biopharm Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TTY Biopharm Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.92.
TTY Biopharm Co (ROCO:4105) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
TTY Biopharm Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TTY Biopharm Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
TTY Biopharm Co Total Inventories Related Terms
TTY Biopharm Co Total Inventories Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of NT$1,406 Mil mean?
TTY Biopharm Co (ROCO:4105) has a Total Inventories of NT$1,406 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for TTY Biopharm Co and its competitors.
Is TTY Biopharm Co's Total Inventories too high?
TTY Biopharm Co's current Total Inventories is NT$1,406 Mil. Overall, TTY Biopharm Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Total Inventories compare to ZTS and UTHR?
TTY Biopharm Co's Total Inventories of NT$1,406 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for TTY Biopharm Co and its competitors. TTY Biopharm Co's current Total Inventories is NT$1,406 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.58, compared to a current price of NT$77.00 — trading 12.1% below its estimated fair value. The current Total Inventories is NT$1,406 Mil. TTY Biopharm Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Total Inventories is NT$1,406 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$77.00 is trading 12.1% below its estimated GF Value™ of NT$87.58.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Total Inventories: NT$1,406 Mil
GF Value™: NT$87.58 vs. price of NT$77.00 (12.1% below fair value)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
84GF Score
Get the complete analysis for ROCO:4105
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
